Text Size

Non Steroidal Antiinflammatory Drugs Influence on Heal of Colles Fracture (CHIP)

This study is currently recruiting participants.
Verified September 2012 by Aalborg Universityhospital
Sponsor:
Information provided by (Responsible Party):
Marius Aliuskevicius, Aalborg Hospital
ClinicalTrials.gov Identifier:
NCT01567072
First received: March 20, 2012
Last updated: September 24, 2012
Last verified: September 2012
History of Changes
  Purpose

It is believed, that Non Steroidal Antiinflammatory Drug (NSAID) drugs slows bone healing, but the knowledge is based only on animal studies, and the results are automatically raised for the people.

Many patients with bone fracture must therefore avoid the formerly so popular and good painkillers, although no clinical trial evidence is, that this medicine is really harmful for patients with fractures.

The purpose of this study is to investigate whether these drugs slows bone healing, and what the relationship is between various bone studies - DEXA scanning, biochemical bone marker tests, radiographic controls and tissue examination of newly formed bone under a microscope. How sensitive and specific, each of the above study methods? If they are just as sensitive, the cheapest of them recommended as a routine investigation on suspicion of bone effects. Furthermore, to compare the benefit (pain-relieving effect, influence on rehabilitation) of these drugs and their possible harmful side effects (affected and delayed bone healing).

The expectation is that the study may contribute to increased knowledge about NSAIDs effect do pain management, rehabilitation and the entire treatment process significantly easier and safer, so that patients recover faster and return to usual activities.


Condition Intervention Phase
Forearm Fracture
 Drug: Ibuprofen
Drug: Placebo
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Fractures
U.S. FDA Resources

Further study details as provided by Aalborg Universityhospital:

Primary Outcome Measures:
  • Evaluation of changes of fractures position by X rays investigation [ Time Frame: 1 week, 2 weeks, 6 weeks ] [ Designated as safety issue: Yes ]
    Measurement of possible secondary dislocation

  • Evaluation of changes in value of biochemical bone markers [ Time Frame: 1 week, 2 weeks, 6 weeks, 12 weeks, 52 weeks. ] [ Designated as safety issue: Yes ]
    Helps to evaluate process of bone resorbtion and formation


Secondary Outcome Measures:
  • DEXA - scanning [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
    Evaluation of bone density


Estimated Enrollment: 192
Study Start Date: April 2012
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NSAIDs in 7 days
NSAIDs (Ibuprofen) in 7 days
 Drug: Ibuprofen
Treatment with Ibuprofen 600mg 3times a day in 7 days after Colles fracture diagnosis
Active Comparator: NSAIDs in 3 days
NSAIDs (Ibuprofen) in the first 3 days and placebo in the last 4 days
 Drug: Ibuprofen
Treatment with Ibuprofen 600mg 3 times daily in 3 days after´diagnosis - Colles fracture
Placebo Comparator: Placebo
Only placebo in 7 days
 Drug: Placebo
Only placebo treatment instead of NSAID painkillers

  Eligibility

Ages Eligible for Study:   50 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • written acceptance to participate in the study
  • immobilisation or reposition or surgery demanding Colles fracture (which needs to be fixed with external fixation).

Exclusion Criteria:

  • age - younger than 50 years or older than 80 years
  • treatment with prednisolon
  • NSAIDs - treatment
  • previous fracture or surgery at the wrist
  • lack of mental and physical capacity to follow studies' instructions
  • lack of informed consent
  • other diseases can affect bone substance (oncology, endocrine diseases)
  • medical contraindications to NSAIDs use
  • smoking, alcohol consumption of more than 14 drinks per week
  • secondary dislocation of fracture also apply as exclusion criterion.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01567072

Contacts
Contact: Marius Aliuskevicius, Master of Medicin +45 26910156 aliuskevicius@yahoo.dk
Contact: Jane Dorthea Livoni +45 99369118 jane.dorthea.livoni@rn.dk

Locations
Denmark
Department of Orthopaedic Surgery, Aalborg University Hospital Recruiting
Aalborg, Denmark, 9000
Contact: Marius Aliuskevicius, Master of Medicine     +45 99325195     marali@rn.dk    
Principal Investigator: Marius Aliuskevicius, Master of Medicine            
Sponsors and Collaborators
Marius Aliuskevicius
  More Information

Additional Information:
Hospitals Unit for Research in Orthopaedics  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: Marius Aliuskevicius, Principal Investigator, Aalborg Hospital
ClinicalTrials.gov Identifier: NCT01567072     History of Changes
Other Study ID Numbers: 2010-018543-34
Study First Received: March 20, 2012
Last Updated: September 24, 2012
Health Authority: Denmark: Danish Medicines Agency

Keywords provided by Aalborg Universityhospital:
NSAID
bone fracture
heal

Additional relevant MeSH terms:
Colles' Fracture
Fractures, Bone
Radius Fractures
Wounds and Injuries
Anti-Inflammatory Agents
Ibuprofen
Anti-Inflammatory Agents, Non-Steroidal
Therapeutic Uses
Pharmacologic Actions
Analgesics, Non-Narcotic
 Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 23, 2013